Form 4: STERIS plc Executive Acquires Shares and Options in Recent Transaction
SEC Form 4 Filing
SVP and President of Healthcare at STERIS plc, Cary L. Majors, reports acquisition of shares and options, indicating changes in beneficial ownership.
Summary
- On June 4, 2024, Cary L. Majors, SVP and President, Healthcare at STERIS plc, acquired 2,379 ordinary shares at $0 price.
- Following the transaction, Majors directly owns 13,054 ordinary shares, including 9,872 restricted shares that vest over time.
- Majors also indirectly owns 67 ordinary share equivalents through the STERIS Corporation 401(k) Plan as of May 31, 2024.
- Majors acquired options to purchase 12,200 ordinary shares at an exercise price of $251.34, which become exercisable in installments starting June 4, 2025.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive is generally seen as a positive sign, indicating confidence in the company's future. However, without additional context, it's difficult to gauge the full impact.
Positives
- The acquisition of shares and options by a high-ranking executive could be interpreted as a sign of confidence in the company's future performance.
Industry Context
Executive stock ownership is a common practice in publicly traded companies like STERIS plc. It aligns management's interests with those of shareholders and can serve as a motivation for long-term value creation.
Stakeholder Impact
- The reported transactions may have a minor positive impact on shareholder sentiment, as they reflect an executive's investment in the company.
Key Dates
| Date | Description |
|---|---|
| May 31, 2024 | Date for ordinary share equivalents held in STERIS Corporation 401(k) Plan. |
| June 4, 2024 | Date of the transaction involving the acquisition of ordinary shares and stock options. |
| June 2, 2025 | First vesting date for 1,964 restricted ordinary shares. |
| October 1, 2025 | Second vesting date for 692 restricted ordinary shares. |
| June 1, 2026 | Third vesting date for 2,697 restricted ordinary shares. |
| June 2, 2026 | Fourth vesting date for 2,140 restricted ordinary shares. |
| June 4, 2027 | Fifth vesting date for 2,379 restricted ordinary shares. |
| June 4, 2025 | First date that 3,050 of the acquired stock options become exercisable. |
| June 4, 2026 | Second date that 3,050 of the acquired stock options become exercisable. |
| June 4, 2027 | Third date that 3,050 of the acquired stock options become exercisable. |
| June 5, 2028 | Fourth date that 3,050 of the acquired stock options become exercisable. |
| June 4, 2034 | Expiration date for the acquired stock options. |
| June 6, 2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.